Bc Cancer

SAN DIEGO — The addition of tafasitamab-cxix to lenalidomide and rituximab reduced risk for progression, relapse or death by more than 50% for patients with relapsed or refractory follicular lymphoma, according to study results.

SAN FRANCISCO  — The addition of niraparib to abiraterone acetate and prednisone improved outcomes for certain men with prostate cancer, according to randomized phase 3 study results presented at ASCO Genitourinary Cancers Symposium.